CA2556794A1 - Le beta-lapachone est un agent anticancereux a large spectre - Google Patents

Le beta-lapachone est un agent anticancereux a large spectre Download PDF

Info

Publication number
CA2556794A1
CA2556794A1 CA002556794A CA2556794A CA2556794A1 CA 2556794 A1 CA2556794 A1 CA 2556794A1 CA 002556794 A CA002556794 A CA 002556794A CA 2556794 A CA2556794 A CA 2556794A CA 2556794 A1 CA2556794 A1 CA 2556794A1
Authority
CA
Canada
Prior art keywords
cancer
lapachone
pharmaceutically acceptable
acceptable salt
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002556794A
Other languages
English (en)
Inventor
Chiang J. Li
Youzhi Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2556794A1 publication Critical patent/CA2556794A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention fournit des procédés qui utilisent des agents efficaces dans le traitement d'un large éventail d'affections cancéreuses et précancéreuses. De plus, la présente invention fournit des agents capables de servir d'inhibiteur de la prolifération de cellules sur un large éventail de types de cellules.
CA002556794A 2004-02-20 2005-02-18 Le beta-lapachone est un agent anticancereux a large spectre Abandoned CA2556794A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54591604P 2004-02-20 2004-02-20
US60/545,916 2004-02-20
PCT/US2005/005647 WO2005082358A2 (fr) 2004-02-20 2005-02-18 Le bêta-lapachone est un agent anticancereux à large spectre

Publications (1)

Publication Number Publication Date
CA2556794A1 true CA2556794A1 (fr) 2005-09-09

Family

ID=34910740

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002556794A Abandoned CA2556794A1 (fr) 2004-02-20 2005-02-18 Le beta-lapachone est un agent anticancereux a large spectre

Country Status (4)

Country Link
EP (1) EP1722776A2 (fr)
JP (1) JP2007523192A (fr)
CA (1) CA2556794A1 (fr)
WO (1) WO2005082358A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
CA2595564C (fr) * 2005-02-16 2015-03-31 Md Bioalpha Co., Ltd. Composition pharmaceutique pour le traitement ou la prevention de pathologies comprenant l'obesite, le diabete, les syndromes metaboliques, les maladies neurodegeneratives, et lesmaladies liees a une dysfonction mitochondriale
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
WO2013153821A1 (fr) * 2012-04-12 2013-10-17 Omura Satoshi Inhibiteur de pdk4 et son utilisation
CN114630662A (zh) * 2020-10-08 2022-06-14 科罗姆生物科技有限公司 包含β-拉帕醌作为有效成分的用于预防或治疗胆汁淤积性肝病的药学组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
AU2003254029A1 (en) * 2002-07-17 2004-02-02 Arqule, Inc. Activated checkpoint therapy and methods of use thereof
TW200510367A (en) * 2002-11-18 2005-03-16 Arqule Inc Novel lapachone compounds, their preparation, and the use thereof
EP1575580A4 (fr) * 2002-12-02 2009-06-10 Arqule Inc Methodes de traitement de cancers

Also Published As

Publication number Publication date
WO2005082358A2 (fr) 2005-09-09
EP1722776A2 (fr) 2006-11-22
JP2007523192A (ja) 2007-08-16
WO2005082358A3 (fr) 2005-12-15

Similar Documents

Publication Publication Date Title
US7361691B2 (en) Method of treating cancers using β-lapachone or analogs or derivatives thereof
US6214821B1 (en) Methods and composition for the inhibition of cancer cells
US20190134044A1 (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
CA2556794A1 (fr) Le beta-lapachone est un agent anticancereux a large spectre
CA2556789A1 (fr) Utilisation de beta-lapachone pour traiter des tumeurs hematologiques
Behera et al. Implication of methylselenocysteine in combination chemotherapy with gemcitabine for improved anticancer efficacy
EP2033640A2 (fr) Béta-lapachone pour le traitement du cancer des poumons
US20050192360A1 (en) Method of treatment of pancreatic cancer
EP2033638A2 (fr) Béta-lapachone pour le traitement du cancer pancréatique
CA2556759A1 (fr) Combinaisons de beta-lapachone et de medicament en phase s pour le traitement du cancer
Markowicz-Piasecka et al. Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells
US20050197405A1 (en) Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US20050222246A1 (en) Beta-lapachone is a broad spectrum anti-cancer agent
US20050197406A1 (en) Method of treatment of lung cancer
WO2007132220A1 (fr) Combinaison de 4-hétér0aryl-pyrimidine amine substituée en 2 et d'un médicament cytotoxique, son utilisation dans le traitement d'un trouble prolifératif
US20050192361A1 (en) Method of treatment of colon cancer
EP2033639A2 (fr) Béta-lapachone pour le traitement du cancer du colon
Parekh et al. Circumvention of adriamycin resistance: effect of 2-methyl-1, 4-naphthoquinone (vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells
Hsu et al. 2-(3-Fluorophenyl)-6-methoxyl-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (YJC-1) induces mitotic phase arrest in A549 cells
US20050192247A1 (en) Method of treating cancers
Liu et al. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells
RU2784809C2 (ru) Комбинированный продукт, содержащий дициклоплатин, и способ его получения и применения
KR101046630B1 (ko) Ｓ-아데노실메티오닌을 유효성분으로 함유하는 암세포 특이적인 항암보조용 약제학적 조성물
ITRM20130312A1 (it) Estratto di cynara spp. e suoi usi.
WO2011131636A1 (fr) Polytraitement du cancer à l'aide de benzo[e]pyridoindoles et d'agents de dégradation de l'adn

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20091229